Stoke Therapeutics Inc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All 0GT.MU news ›Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
– Analysis of the Phase 3 EMPEROR key secondary endpoint of changes in cognition and behavior will be performed using a multicomponent assessment of four Vineland-3 subdomains – – Phase 3 readout anticipated in the third quarter of 2027 to…
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDT Thomas Leggett - Chief Financial OfficerIan Smith - CEO & DirectorBarry Ticho - Chief Medical OfficerJason Hoitt - Chief Patient Officer Good day, and thank…
More from 1 other outlet
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
– Company announces positive interim data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome – – Single and multiple doses of STK-001 up to 45mg were well-tolerated – – 55% median…
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
– Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program – Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett syndrome (MECP2) and undisclosed…
Stoke Therapeutics (STOK) Set to Announce Quarterly Earnings on Thursday
Posted by Mitch Edgeman on Oct 27th, 2026 STOK opened at $25.46 on Tuesday. The company has a market capitalization of $1.64 billion, a P/E ratio of -7.62 and a beta of 1.26. The firm’s fifty day moving average price is $28.02 and its…
Head to Head Contrast: ImageneBio (NASDAQ:IMA) vs. Stoke Therapeutics (NASDAQ:STOK)
Posted by Mitch Edgeman on Oct 27th, 2026 Stoke Therapeutics (NASDAQ:STOK – Get Free Report) and ImageneBio (NASDAQ:IMA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two…
Stoke Therapeutics: The Market Misread A Key FDA Win
Explore Stoke Therapeutics (STOK) ahead of the 2027 zorevunersen Dravet readout—cash runway to 2028, FDA endpoint edge, and upside valuation. - Stoke Therapeutics is positioned for a pivotal 2027 readout of zorevunersen, potentially the…
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - October 16, 2026
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. The…
More from 1 other outlet
Stoke Therapeutics, Inc. Announces Board and Committee Changes, Effective September 23, 2026
Stoke Therapeutics, Inc. announced that on September 22, 2026, Edward M. Kaye, M.D. notified the Board of Directors of the company of his intent to resign as a Class III director of the Board, and as... announced that on September 22,…
Stoke Therapeutics Announces Appointment of Thomas McCauley as Chief Scientific Officer
Stoke Therapeutics, Inc. announced that Thomas McCauley, Ph.D., had been appointed Chief Scientific Officer. Dr. McCauley joined Stoke with more than 25 years of experience leading high-performing R&D... announced that Thomas McCauley,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com8
- defenseworld.net2
- investor.stoketherapeutics.com2
- seekingalpha.com2
- themarketsdaily.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.